Physician samples valuation by comparable trade packs upheld; disclosure in declarations defeated extended limitation and penalties.

Physician samples may be valued under the Central Excise Valuation Rules by reference to comparable trade packs, with suitable adjustment where necessary, rather than by the assessee's cost-based method. The valuation adopted in substance followed the comparative goods principle, so the challenge to that approach failed. Where the assessee had filed declarations and disclosed the valuation basis, suppression with intent to evade duty was not established and the extended period could not be invoked. As a result, duty was confined to the normal limitation period, while penalty under Section 11AC, interest under Section 11AB, and related penalties on company officers were not sustainable.

---

---

Issues: (i) Whether the value of physician samples was correctly determined by reference to comparable trade packs rather than under the assessee's cost-based method. (ii) Whether the extended period of limitation, penalty and interest were sustainable in the facts of the case.

Issue (i): Whether the value of physician samples was correctly determined by reference to comparable trade packs rather than under the assessee's cost-based method.

Analysis: Physician samples are not assessable under Section 4 of the Central Excise Act and must be valued under the Valuation Rules. The Tribunal held that physician samples are comparable with regular trade packs and that value can be derived by applying the principle of comparable goods, with suitable adjustment where necessary. The valuation adopted by the adjudicating authority, though described under the wrong rule, was in substance based on the correct comparative method and not on the cost-construction method adopted by the assessee.

Conclusion: The value of physician samples was not to be determined under the assessee's cost-based method, and the comparative trade-pack method was upheld.

Issue (ii): Whether the extended period of limitation, penalty and interest were sustainable in the facts of the case.

Analysis: The assessee had filed declarations under Rule 173C and disclosed the valuation basis. The department was therefore aware of the manner in which value was being worked out, and suppression with intent to evade duty was not established. The larger period could not be invoked, although duty for the normal period remained payable. In the absence of suppression, penalty under Section 11AC, interest under Section 11AB, and penalties on the company officers were not sustainable.

Conclusion: The extended period and the connected penalties and interest were set aside, while duty for the normal period was sustained.

Final Conclusion: The demand was sustained only to the extent of the normal limitation period on the company, while the penalties and interest were deleted and the appeals of the director and administrative manager succeeded in full.

Ratio Decidendi: Physician samples may be valued on the basis of comparable trade goods under the valuation rules, and disclosure of the valuation basis in statutory declarations negates suppression for invoking the extended period.

---